Page last updated: 2024-09-04

rupatadine and Diabetic Glomerulosclerosis

rupatadine has been researched along with Diabetic Glomerulosclerosis in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Abdel-Hakeem, EA; Hafez, HM; Hassanein, H	1

Other Studies

1 other study(ies) available for rupatadine and Diabetic Glomerulosclerosis

Article	Year
Rupatadine, a dual antagonist of histamine and platelet-activating factor (PAF), attenuates experimentally induced diabetic nephropathy in rats. Naunyn-Schmiedeberg's archives of pharmacology, 2020, Volume: 393, Issue:8 Topics: Animals; Blood Glucose; Cyclin-Dependent Kinase Inhibitor p21; Cyproheptadine; Cystatin C; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Histamine Antagonists; Kidney; Male; Oxidative Stress; Platelet Activating Factor; Rats; Streptozocin; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Tumor Suppressor Protein p53	2020

Article

Year

Rupatadine, a dual antagonist of histamine and platelet-activating factor (PAF), attenuates experimentally induced diabetic nephropathy in rats.

Naunyn-Schmiedeberg's archives of pharmacology, 2020, Volume: 393, Issue:8

Topics: Animals; Blood Glucose; Cyclin-Dependent Kinase Inhibitor p21; Cyproheptadine; Cystatin C; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Histamine Antagonists; Kidney; Male; Oxidative Stress; Platelet Activating Factor; Rats; Streptozocin; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Tumor Suppressor Protein p53

2020